Cargando…

Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients

The protein therapeutic and CD95L inhibitor asunercept is currently under clinical investigation for the treatment of glioblastoma and myelodysplastic syndrome. The purpose of this study was to predict the asunercept pharmacokinetics in children and to give dose recommendations for its first use in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanke, Nina, Kunz, Claudia, Thiemann, Meinolf, Fricke, Harald, Lehr, Thorsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523206/ https://www.ncbi.nlm.nih.gov/pubmed/30939793 http://dx.doi.org/10.3390/pharmaceutics11040152

Ejemplares similares

Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile
por: Radujkovic, Aleksandar, et al.
Publicado: (2020)

Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients
por: Wick, Wolfgang, et al.
Publicado: (2019)

Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies
por: Krendyukov, Andriy, et al.
Publicado: (2019)

Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study
por: Wei, Kuo-Chen, et al.
Publicado: (2021)

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
por: Hanke, Nina, et al.
Publicado: (2018)

Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients
por: Kovar, Lukas, et al.
Publicado: (2020)

The dual role of the CD95 and CD95L signaling pathway in glioblastoma
por: Zhang, Yanrui, et al.
Publicado: (2022)

Infiltration of circulating myeloid cells through CD95L contributes to neurodegeneration in mice
por: Gao, Liang, et al.
Publicado: (2015)

Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates
por: Kovar, Lukas, et al.
Publicado: (2020)

Comprehensive Parent–Metabolite PBPK/PD Modeling Insights into Nicotine Replacement Therapy Strategies
por: Kovar, Lukas, et al.
Publicado: (2020)

Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro
por: Merz, Christian, et al.
Publicado: (2015)

The role of CD95 and CD95 ligand in cancer
por: Peter, M E, et al.
Publicado: (2015)

CD95 gene deletion may reduce clonogenic growth and invasiveness of human glioblastoma cells in a CD95 ligand-independent manner
por: Quijano-Rubio, Clara, et al.
Publicado: (2022)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence
por: Rostami‐Hodjegan, Amin
Publicado: (2017)

A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity
por: Thiemann, Meinolf, et al.
Publicado: (2018)

PBPK-PD modeling for the preclinical development and clinical translation of tau antibodies for Alzheimer’s disease
por: Bloomingdale, Peter, et al.
Publicado: (2022)

Maximum Recommended Dosage of Lithium for Pregnant Women Based on a PBPK Model for Lithium Absorption
por: Horton, Scott, et al.
Publicado: (2012)

A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions
por: Türk, Denise, et al.
Publicado: (2020)

Modulation of the CD95-Induced Apoptosis: The Role of CD95 N-Glycosylation
por: Shatnyeva, Olga M., et al.
Publicado: (2011)

The CD95/CD95L Signaling Pathway: A Role in Carcinogenesis
por: Fouqué, Amélie, et al.
Publicado: (2014)

The CD95/CD95L Signaling Pathway: A Role in Carcinogenesis
por: Fouqué, Amélie, et al.
Publicado: (2020)

Performance Evaluation of Montelukast Pediatric Formulations: Part II — a PBPK Modelling Approach
por: Guimarães, Mariana, et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases
por: Risso, Vesna, et al.
Publicado: (2022)

PBPK modeling and simulation in drug research and development
por: Zhuang, Xiaomei, et al.
Publicado: (2016)

Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis
por: Fuhr, Laura Maria, et al.
Publicado: (2020)

Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene
por: Moers, C, et al.
Publicado: (2001)

Trigeminal neuralgia causes neurodegeneration in rats associated with upregulation of the CD95/CD95L pathway
por: Wang, Lu, et al.
Publicado: (2020)

CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells
por: Drachsler, M, et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2022)

Feasibility of a Pragmatic PBPK Modeling Approach: Towards Model-Informed Dosing in Pediatric Clinical Care
por: van der Heijden, Joyce E. M., et al.
Publicado: (2022)

Formulation development, in vivo bioequivalence and pediatric PBPK modeling studies of taste-masked ciprofloxacin chewable tablets
por: Usmani, Muhammad Talha, et al.
Publicado: (2023)

Health Risk Assessment in Children Occupationally and Para-Occupationally Exposed to Benzene Using a Reverse-Translation PBPK Model
por: Pech, Kristal, et al.
Publicado: (2023)

A Workflow for Global Sensitivity Analysis of PBPK Models
por: McNally, Kevin, et al.
Publicado: (2011)

PBPK Modeling on Organs-on-Chips: An Overview of Recent Advancements
por: Yang, Yi, et al.
Publicado: (2022)

Permeability of Gemcitabine and PBPK Modeling to Assess Oral Administration
por: Ferreira, Abigail, et al.
Publicado: (2021)

The Expression and Prognostic Impact of CD95 Death Receptor and CD20, CD34 and CD44 Differentiation Markers in Pediatric Acute Lymphoblastic Leukemia
por: M. Kamazani, Fatemeh, et al.
Publicado: (2014)

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III
por: Witkowski, Jakub, et al.
Publicado: (2023)

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part II
por: Witkowski, Jakub, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_04r19daqp5hkcc3ijoqs9321ag